Brucellosis is a zoonotic infection, a systemic, infectious and metabolic disease caused by Brucella infection. Brucellosis spondylitis (BS) has an incidence of 2%-65% in brucellosis and is a purulent inflammation caused by infection of the intervertebral discs and vertebral tissues. The pathological manifestations are mainly the inflammatory changes of the intervertebral disc. Its occurrence has obvious geographical characteristics, clinical symptoms can be manifested as low back pain and fever. 1, drug treatment 1) drug treatment indications and principles The indications for drug treatment of brucellosis spondylitis mainly include: ① early primary cases; ② acute phase without neurological impairment; ③ local symptoms of the spine are mild, while systemic symptoms such as intermittent hypothermia, night sweats, weakness and loss of appetite are predominant; ④ spinal stability is good, and the foci of destruction are less than 25px; ⑤ there is no intradiscal abscess, intervertebral disc (5) no intra-vertebral abscess, intervertebral disc destruction and paravertebral soft tissue swelling. The drug treatment followed the principle of “long-term, adequate, combined, and multi-drug administration”, and the appropriate antimicrobial agent was selected according to the results of drug sensitivity test, and the drug treatment was carried out throughout the treatment process. The WHO recommended treatment regimen is: doxycycline 200 mg/d + rifampicin 600-900 mg/d for 6 w; doxycycline 200 mg/d (tetracycline 2 g/d) + streptomycin 1 g/d for 6 w; doxycycline 200 mg/d (tetracycline 2 g/d) + streptomycin 1 g/d for 6 w. Domestic and foreign scholars have found that the efficiency of this treatment regimen is only 60%, and its recurrence rate is 14.4%-60%. According to the “Brucellosis Treatment Guidelines (Trial)” issued by the Ministry of Health of China in 2012, the treatment plan adopted by our hospital for patients with brucellosis combined with spondylitis is: doxycycline 200mg /d + rifampicin 600mg/d + quinolones and three generations of cephalosporins for 2w. 2, surgical treatment 1) Indications for surgery Surgical treatment of brucellosis spondylitis is performed on the basis of non-surgical drug The purpose is to effectively remove the lesion, release the spinal cord or nerve root compression, maintain and rebuild the stability of the spine, and relieve pain. Surgery is considered to be the last option for the treatment of brucellosis spondylitis. The indications for surgery for B. burgdorferi spondylitis vary in the domestic and international literature, but are generally considered to include: (1) persistent low back pain that cannot be relieved by non-surgical treatment, or that is caused by disc destruction or intervertebral infection; (2) intradural epidural abscesses or inflammatory granulation tissue or necrotic prolapsed disc tissue compressing the spinal cord or nerve roots or cauda equina; (3) paravertebral abscesses that are significantly difficult to absorb; (4) foci of bone destruction in the vertebral body; and (5) foci of bone destruction in the vertebral body. of the vertebral body; ④ vertebral bone destruction foci greater than 25px or joint breakthrough bad affect spinal stability; ⑤ combined with pathological fractures. (2) Surgical approach The surgical approaches for brucellosis spondylitis include anterior approach, posterior approach, combined anterior-posterior approach and anterolateral approach, and the surgical methods include focal clearance implant fusion and focal clearance intervertebral implant fusion internal fixation. 3, minimally invasive surgical treatment In recent years, minimally invasive surgery for brucellosis spondylitis has been used clinically as an effective treatment method. Minimally invasive surgery mainly includes percutaneous intervertebral disc aspiration and tube placement irrigation and drainage and abscess aspiration and tube placement irrigation and drainage. It is mainly applied to those who have simple intervertebral disc destruction or paravertebral abscess, and whose systemic symptoms have improved after drug treatment, but whose local symptoms have not been significantly relieved. 4.Efficacy evaluation standard Clinical efficacy evaluation is expressed as “excellent”, “good” and “poor”. ①Excellent: normal temperature, complete relief of back pain, complete recovery of daily activities, negative RBP, stable spine on X-ray, disappearance or calcification of abscess on CT, clear outline of lesion margin, and repair of bone destruction foci; ②Good: normal temperature, ≥50% relief of back pain, >50% recovery of daily activities, negative RBP, stable or unstable spine on X-ray, abscess on CT shrinkage, clearer outline of lesion edges, and repair of damaged bone; ③poor: fluctuation of body temperature, relief of low back pain <50%, recovery of daily activity <50%, negative or positive RBP, stable or unstable spine on X-ray, no significant change or improvement in CT performance compared with preoperative, or recurrence.